HUP0200942A2 - Humán hepatitisz-C kezelése antioxidánsokkal társított ribavirint tartalmazó kombinációkkal - Google Patents

Humán hepatitisz-C kezelése antioxidánsokkal társított ribavirint tartalmazó kombinációkkal

Info

Publication number
HUP0200942A2
HUP0200942A2 HU0200942A HUP0200942A HUP0200942A2 HU P0200942 A2 HUP0200942 A2 HU P0200942A2 HU 0200942 A HU0200942 A HU 0200942A HU P0200942 A HUP0200942 A HU P0200942A HU P0200942 A2 HUP0200942 A2 HU P0200942A2
Authority
HU
Hungary
Prior art keywords
antioxidants
association
combination therapy
hcv combination
containing ribavirin
Prior art date
Application number
HU0200942A
Other languages
English (en)
Inventor
Clifford A. Brass
Paul W. Glue
Edward Piken
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of HUP0200942A2 publication Critical patent/HUP0200942A2/hu
Publication of HUP0200942A3 publication Critical patent/HUP0200942A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
HU0200942A 1999-04-19 2000-04-18 Hcv combination therapy, containing ribavirin in association with antioxidants HUP0200942A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29468799A 1999-04-19 1999-04-19

Publications (2)

Publication Number Publication Date
HUP0200942A2 true HUP0200942A2 (hu) 2002-07-29
HUP0200942A3 HUP0200942A3 (en) 2003-03-28

Family

ID=23134504

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0200942A HUP0200942A3 (en) 1999-04-19 2000-04-18 Hcv combination therapy, containing ribavirin in association with antioxidants

Country Status (14)

Country Link
EP (1) EP1046399A1 (hu)
JP (1) JP2002542202A (hu)
CN (1) CN1355708A (hu)
AR (1) AR023541A1 (hu)
AU (1) AU4463300A (hu)
BR (1) BR0009840A (hu)
CA (1) CA2306039A1 (hu)
CO (1) CO5241354A1 (hu)
HU (1) HUP0200942A3 (hu)
MX (1) MXPA00003974A (hu)
NO (1) NO20015059L (hu)
PE (1) PE20010284A1 (hu)
WO (1) WO2000062799A1 (hu)
ZA (1) ZA200108571B (hu)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
PL364995A1 (en) 2000-02-18 2004-12-27 Shire Biochem Inc. Method for the treatment or prevention of flavivirus
AU2002225870B2 (en) * 2000-11-03 2006-09-21 Intarcia Therapeutics, Inc. Method for short-term and long-term drug dosimetry
ITMI20011863A1 (it) * 2001-09-05 2003-03-05 Zambon Spa Associazione di farmaci contro il virus dell'influenza
WO2003024461A1 (en) * 2001-09-20 2003-03-27 Schering Corporation Hcv combination therapy
US20040022873A1 (en) * 2001-11-09 2004-02-05 Guilford F. Timothy Systemic administration of NAC as an adjunct in the treatment of bioterror exposures such as anthrax, smallpox or radiation and for vaccination prophylaxis, and use in combination with DHEA for the treatment of smallpox and other viruses
TWI274585B (en) * 2002-06-03 2007-03-01 Nat Health Research Institutes Pharmaceutical composition, kit, and packaged product for treating infection by a flaviviridae virus
CA2509955A1 (en) * 2002-11-29 2004-06-17 Gpc Biotech Ag Formulations useful against hepatitis c virus infections
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20060088502A1 (en) * 2003-02-21 2006-04-27 Michio Sata Drug for reducing side effects in ribavirin interferon combination therapy
ZA200601181B (en) * 2003-08-13 2007-04-25 Smith Howard J & Ass Pty Ltd Method of treating viral infections
WO2005120479A1 (en) * 2004-06-09 2005-12-22 Gpc Biotech Ag Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
JP5143131B2 (ja) 2006-05-30 2013-02-13 インターシア セラピューティクス，インコーポレイティド 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
NZ598686A (en) 2009-09-28 2014-05-30 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20130129680A1 (en) * 2011-11-23 2013-05-23 Thomas Christian Lines Method for treating hepatitis c virus infection using quercetin-containing compositions
WO2014018567A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
CA2890111A1 (en) 2012-11-02 2014-05-08 Pharmacyclics, Inc. Tec family kinase inhibitor adjuvant therapy
JP2017509336A (ja) 2014-03-20 2017-04-06 ファーマサイクリックス エルエルシー ホスホリパーゼｃガンマ２及び耐性に関連した変異
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5157998A (en) * 1996-11-01 1998-05-29 Thomas Najarian Methods and compositions for treatment of hepatitis c infection

Also Published As

Publication number Publication date
CO5241354A1 (es) 2003-01-31
AU4463300A (en) 2000-11-02
CN1355708A (zh) 2002-06-26
JP2002542202A (ja) 2002-12-10
EP1046399A1 (en) 2000-10-25
MXPA00003974A (es) 2002-03-08
CA2306039A1 (en) 2000-10-19
WO2000062799A1 (en) 2000-10-26
HUP0200942A3 (en) 2003-03-28
BR0009840A (pt) 2002-01-08
ZA200108571B (en) 2003-01-20
PE20010284A1 (es) 2001-03-05
NO20015059D0 (no) 2001-10-18
AR023541A1 (es) 2002-09-04
NO20015059L (no) 2001-12-19

Similar Documents

Publication Publication Date Title
HUP0200942A3 (en) Hcv combination therapy, containing ribavirin in association with antioxidants
DE69927412D1 (en) Phosphitadditive in polyolefinen
TW475749U (en) Fan plate with fast-plugging/unplugging fan body
IL146907A0 (en) An arrangement in an electronics system
IL165521A0 (en) Interferon-beta in HCV
EP1242064A4 (en) LIFE-SPECIFIC THERAPY
GB2359044B (en) Laminates
GB9928184D0 (en) Improvements in ofdm transmitters and recievers
GB2356437B (en) Improvements in swashplate design
GB2349803B (en) Improvements in shelving
GB9905305D0 (en) Improvements in vehicles
GB2335410B (en) Improvements in pouches
GB2390398B (en) Improvements in pumps
GB2357459B (en) Improvements in books
GB9902641D0 (en) Magic juicy
GB9926171D0 (en) Improved laminate
CA87606S (en) Padlock body
GB9916785D0 (en) Laminates
GB9920216D0 (en) Three in one
GB2349831B (en) Body exerciser
GB9804091D0 (en) Improvements in keyholders
GB9909067D0 (en) Combination therapy
TW410932U (en) Improvement in flashlight structure
AU138256S (en) Low back chair
GB9821982D0 (en) Foam laminates